Drs. Karpecki and Schaeffer Discuss the Pharmacological Presbyopia Treatment Consensus Statement

This activity is supported by an unrestricted educational grant from Orasis Pharmaceuticals.

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Define the ideal pre-cataract presbyopia patient for pharmacological treatment, including age ranges, refractive error levels, key demographics, and other clinical and socioeconomic parameters
• Determine how to diagnose the pre-cataract presbyopia patient
• Compare and contrast the advantages and disadvantages of the various pharmacological presbyopia treatments, including efficacy, safety, and functionality
• Identify best practices on how to identify, communicate and educate the pre-cataract patient

Accreditation and Designation Statement

Sponsored by:

Evolve Medical Education LLC (Evolve) is an approved COPE administrator.
This activity, COPE Activity Number 122236, is accredited by COPE for continuing education for optometrists. 
This course is approved for .25 hours of CE. 
Course #:  73469-AS
Activity ID: 122236

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Paul M. Karpecki, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan/AbbVie, Eyenovia, Ocuphire, and Orasis. Stock/Shareholder: Ocuphire and Orasis.

Jack L. Schaeffer, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Mati Therapeutics, Orasis, and Visus. Speaker’s Bureau: Alcon Vision, Allergan, Bausch + Lomb, Mati Therapeutics, Novartis, and Precipt. Stock/Shareholder: Mati Therapeutics, Orasis, Precipt, and Tearfilm.

 Evolve and The Fundingsland Group planners have no financial relationships with commercial interests. 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Orasis Pharmaceuticals.